Core Laboratories N.V. (CLB) EPS Estimated At $0.58

January 18, 2018 - By Hazel Jackson

 Core Laboratories N.V. (CLB) EPS Estimated At $0.58
Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.01, from 1.08 in 2017Q2. It is negative, as 45 investors sold Core Laboratories N.V. shares while 99 reduced holdings. 42 funds opened positions while 112 raised stakes. 49.25 million shares or 6.07% more from 46.43 million shares in 2017Q2 were reported.
Sustainable Growth Advisers L P invested in 2.71 million shares. California Public Employees Retirement Sys reported 93,348 shares or 0.01% of all its holdings. Moreover, Needham Inv Management Ltd Limited Liability Company has 0.15% invested in Core Laboratories N.V. (NYSE:CLB). Bb&T Securities Ltd Liability Co stated it has 12,053 shares or 0.02% of all its holdings. National Bank Of New York Mellon holds 0.02% or 567,306 shares in its portfolio. Eqis Capital Mgmt Inc has invested 0.03% of its portfolio in Core Laboratories N.V. (NYSE:CLB). Robeco Institutional Asset Mngmt Bv owns 682 shares. Hightower Llc accumulated 0.01% or 10,535 shares. Riverhead Mngmt Llc holds 3,306 shares. Rmb Mngmt Ltd Company has 152,135 shares. Denver Investment Advsr Limited Liability, a Colorado-based fund reported 67,563 shares. 819 were reported by Livforsakringsbolaget Skandia Omsesidigt. Cornerstone reported 0.1% of its portfolio in Core Laboratories N.V. (NYSE:CLB). Evercore Wealth Mngmt Limited accumulated 0.89% or 232,837 shares. State Street holds 1.24 million shares.

Analysts expect Core Laboratories N.V. (NYSE:CLB) to report $0.58 EPS on January, 24.They anticipate $0.17 EPS change or 41.46 % from last quarter’s $0.41 EPS. CLB’s profit would be $25.60 million giving it 50.63 P/E if the $0.58 EPS is correct. After having $0.48 EPS previously, Core Laboratories N.V.’s analysts see 20.83 % EPS growth. The stock decreased 0.30% or $0.35 during the last trading session, reaching $117.45. About 437,349 shares traded. Core Laboratories N.V. (NYSE:CLB) has declined 5.82% since January 18, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Core Laboratories N.V. (NYSE:CLB) Ratings Coverage

Among 23 analysts covering Core Laboratories (NYSE:CLB), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Core Laboratories has $155 highest and $80 lowest target. $113.60’s average target is -3.28% below currents $117.45 stock price. Core Laboratories had 51 analyst reports since August 24, 2015 according to SRatingsIntel. UBS initiated Core Laboratories N.V. (NYSE:CLB) rating on Tuesday, December 13. UBS has “Neutral” rating and $125 target. Cowen & Co maintained Core Laboratories N.V. (NYSE:CLB) rating on Friday, July 7. Cowen & Co has “Hold” rating and $10000 target. Guggenheim upgraded Core Laboratories N.V. (NYSE:CLB) on Monday, November 30 to “Buy” rating. The stock of Core Laboratories N.V. (NYSE:CLB) earned “Hold” rating by Piper Jaffray on Monday, July 24. ABN Amro maintained Core Laboratories N.V. (NYSE:CLB) on Monday, April 24 with “Hold” rating. The stock of Core Laboratories N.V. (NYSE:CLB) earned “Outperform” rating by Credit Suisse on Thursday, August 24. Oppenheimer initiated Core Laboratories N.V. (NYSE:CLB) on Tuesday, January 12 with “Perform” rating. As per Friday, September 1, the company rating was maintained by RBC Capital Markets. The rating was initiated by JP Morgan with “Overweight” on Friday, June 10. On Thursday, July 20 the stock rating was maintained by RBC Capital Markets with “Buy”.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the gas and oil industry in the United States, Canada, and internationally. The company has market cap of $5.19 billion. It operates through three divisions: Reservoir Description, Production Enhancement, and Reservoir Management. It has a 67.5 P/E ratio. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples.

More recent Core Laboratories N.V. (NYSE:CLB) news were published by: which released: “Is Core Laboratories NV (CLB) a Buy?” on January 10, 2018. Also published the news titled: “Core Laboratories’ Fourth Quarter 2017 Webcast At 7:30 AM CST / 2:30 PM CET On …” on January 03, 2018.‘s news article titled: “Core Lab Announces Q1 2018 Quarterly Dividend” with publication date: January 16, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.